Natixis Advisors LLC Boosts Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Natixis Advisors LLC increased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 61.1% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 22,697 shares of the company's stock after purchasing an additional 8,606 shares during the period. Natixis Advisors LLC's holdings in Vaxcyte were worth $2,594,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Riverview Trust Co purchased a new position in shares of Vaxcyte in the third quarter valued at approximately $27,000. Fifth Third Bancorp acquired a new stake in Vaxcyte in the 2nd quarter valued at about $35,000. Blue Trust Inc. grew its position in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock worth $42,000 after buying an additional 93 shares in the last quarter. J.Safra Asset Management Corp raised its holdings in Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock valued at $46,000 after acquiring an additional 526 shares in the last quarter. Finally, Quest Partners LLC acquired a new position in Vaxcyte during the 2nd quarter worth approximately $70,000. Institutional investors and hedge funds own 96.78% of the company's stock.

Wall Street Analysts Forecast Growth

PCVX has been the topic of a number of analyst reports. Mizuho raised their price target on Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research note on Tuesday, September 10th. Bank of America boosted their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. BTIG Research boosted their price target on shares of Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a "buy" rating and set a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Jefferies Financial Group increased their price objective on Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte presently has an average rating of "Buy" and an average price target of $147.50.

Insider Buying and Selling

In other news, CEO Grant Pickering sold 7,098 shares of Vaxcyte stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $109.21, for a total transaction of $775,172.58. Following the completion of the sale, the chief executive officer now directly owns 138,581 shares in the company, valued at approximately $15,134,431.01. This trade represents a 4.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Elvia Cowan sold 5,000 shares of the company's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total value of $538,350.00. Following the completion of the sale, the senior vice president now owns 12,723 shares in the company, valued at approximately $1,369,885.41. This represents a 28.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 102,464 shares of company stock valued at $11,455,576 over the last quarter. Company insiders own 3.10% of the company's stock.

Vaxcyte Stock Up 3.6 %

Shares of PCVX stock traded up $3.16 during mid-day trading on Monday, hitting $91.70. The stock had a trading volume of 1,754,774 shares, compared to its average volume of 907,526. The company's 50-day simple moving average is $107.89 and its 200-day simple moving average is $89.57. Vaxcyte, Inc. has a fifty-two week low of $48.35 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($1.10) by $0.27. During the same quarter last year, the company posted ($0.91) earnings per share. As a group, analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.